References of "Rolin, S."
     in
Bookmark and Share    
Peer Reviewed
See detailPharmacological evaluation of the thromboxane A2 receptor antagonist BM-613
Hanson, Julien ULg; Rolin, S.; De Leval, X. et al

Poster (2003, May)

Detailed reference viewed: 3 (0 ULg)
Peer Reviewed
See detailSynthesis and pharmacological evaluation of BM-613, an original thromboxane A2 antagonist
Hanson, Julien ULg; Rolin, S.; De Leval, X. et al

Poster (2003, May)

Detailed reference viewed: 3 (0 ULg)
Peer Reviewed
See detailEtude de la sélectivité tissulaire d’un nouvel antagoniste des récepteurs au thromboxane A2, le BM-613
Hanson, Julien ULg; Rolin, S.; De Leval, X. et al

Poster (2003, January 31)

Detailed reference viewed: 7 (0 ULg)
Full Text
Peer Reviewed
See detailA dual thromboxane inhibitor and thromboxane receptor antagonist prevents pig myocardial infarction induced by coronary thrombosis
Rolin, S.; Petein, M.; Tchana-Sato, Vincent ULg et al

in European Heart Journal (2003), 24(Suppl. S), 325

Detailed reference viewed: 4 (2 ULg)
Full Text
Peer Reviewed
See detailPharmacological evaluation of the novel thromboxane modulator BM-567 (I/II). Effects of BM-567 on platelet function
Dogné, Jean-Michel ULg; De Leval, X.; Kolh, Philippe ULg et al

in Prostaglandins, Leukotrienes, and Essential Fatty Acids (2003)

Detailed reference viewed: 25 (6 ULg)
Full Text
Peer Reviewed
See detailTherapeutic potential of thromboxane inhibitors in asthma
Dogné, Jean-Michel ULg; De Leval, X.; Benoit, P. et al

in Expert Opinion on Investigational Drugs (2002)

Detailed reference viewed: 19 (0 ULg)
Peer Reviewed
See detailPharmacology of the Thromboxane Receptor Antagonist and Thromboxane Synthase Inhibitor Bm-531
Dogné, J. M.; Rolin, S.; de Leval, X. et al

in Cardiovascular Drug Reviews (2001), 19(2, Summer), 87-96

BM-531 (N-tert-butyl-N'-[(2-cyclohexylamino-5-nitrobenzene)sulfonyl]urea), a torasemide derivative, is a novel noncarboxylic thromboxane receptor antagonist and thromboxane synthase inhibitor. Indeed, its ... [more ▼]

BM-531 (N-tert-butyl-N'-[(2-cyclohexylamino-5-nitrobenzene)sulfonyl]urea), a torasemide derivative, is a novel noncarboxylic thromboxane receptor antagonist and thromboxane synthase inhibitor. Indeed, its affinity for human washed platelet TXA2 receptors labeled with [3H]SQ-29548 (IC50 = 0.0078 microM) is higher than sulotroban (IC50 = 0.93 microM) and SQ-29548 (IC50 = 0.021 microM). Moreover, BM-531 is characterized by a potent antiaggregatory property. Indeed, on one hand, in human citrated platelet-rich plasma BM-531 prevents platelet aggregation induced by arachidonic acid (600 microM) (ED100 = 0.125 microM), U-46619, a stable TXA2 agonist (1 microM) (ED50 = 0.482 microM) or collagen (1 microgram/mL) (percentage of inhibition: 42.9% at 10 microM) and inhibits the second wave of ADP (2 microM)-induced aggregation. On the other hand, when BM-531 is incubated in whole blood from healthy donors, the closure time measured by the recently developed platelet function analyser (PFA-100) is significantly prolonged. In addition, at the concentrations of 10 and 1 microM, BM-531 totally prevents the production of TXB2 by human platelets activated by arachidonic acid. Finally, at 10 microM, BM-531 significantly prevents rat fundus contractions induced by U-46619 but not by prostacyclin. These results suggest that BM-531, which is devoid of the diuretic property of torasemide, can be regarded as a promising antiplatelet agent. [less ▲]

Detailed reference viewed: 12 (0 ULg)
Peer Reviewed
See detailPharmacological evaluation of original sulfonylureas as thromboxane A2 antagonists
Dogne, J. M.; De Leval, X.; Neven, P. et al

Poster (2000, March 04)

Detailed reference viewed: 2 (0 ULg)
Peer Reviewed
See detailCharacterization of antiplatelet activity of ticlopidine and acetylsalicylic acid by PFA-100
Dogne, J.-M.; De Leval, X.; Neven, P. et al

in Fundamental & Clinical Pharmacology (2000), 14

Detailed reference viewed: 12 (0 ULg)
See detailPharmacological evaluation of original sulfonylureas as thromboxane A2 antagonists
Dogne, J.-M.; De Leval, X.; Neven, P. et al

in Fundamental & Clinical Pharmacology (2000), 14

Detailed reference viewed: 2 (0 ULg)
Peer Reviewed
See detailCharacterization of antiplatelet activity of ticlopidine and acetylsalicylic acid by PFA-100
Dogne, J. M.; De Leval, X.; Neven, P. et al

Poster (1999, November 20)

Detailed reference viewed: 8 (0 ULg)
Peer Reviewed
See detailImpact d’antagonistes du thromboxane A2 dérivés du torasémide sur la fonction plaquettaire
Dogne, J. M.; Neven, Ph.; Rolin, S. et al

Poster (1999, May)

Detailed reference viewed: 5 (0 ULg)